Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ELAN
ELAN logo

ELAN Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
24.510
Open
23.845
VWAP
24.14
Vol
10.24M
Mkt Cap
12.10B
Low
23.685
Amount
247.27M
EV/EBITDA(TTM)
15.80
Total Shares
499.45M
EV
15.66B
EV/OCF(TTM)
27.14
P/S(TTM)
2.46
Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.
Show More

Events Timeline

(ET)
2026-06-18
07:30:00
Elanco Animal Health Establishes Elanco Ventures Investment Platform with $25M Commitment
select
2026-06-15 (ET)
2026-06-15
09:00:00
Elanco Animal Health Launches TruCan Ultra Lyme-L4 Vaccine
select
2026-05-18 (ET)
2026-05-18
07:30:00
Elanco Launches New Canine Dermatitis Treatment Befrena
select
2026-05-06 (ET)
2026-05-06
06:40:00
Elanco Q1 Revenue $1.37B Beats Expectations
select
2026-05-06
06:40:00
Elanco Animal Health Raises FY26 Revenue Outlook to $5.01B
select

News

seekingalpha
7.5
06-18seekingalpha
Elanco Animal Health Launches Venture Capital Platform
  • Venture Capital Platform Launch: Elanco Animal Health announced the establishment of Elanco Ventures, a dedicated corporate venture capital platform focusing on therapeutic advancements and supportive technologies in the animal health sector, backed by a $25 million multi-year commitment and set to launch in late 2026, reflecting the company's emphasis on innovation.
  • Investment Focus Defined: Elanco Ventures will prioritize investments in early-stage companies, specifically targeting Pre-Seed, Seed, and Series A stages, aiming to drive technological advancements in the animal health industry and enhance the company's competitive position in the market.
  • Experienced Leadership Team: The platform will be overseen by Eric Steager, an experienced CVC leader, ensuring professional and effective investment decisions that further bolster Elanco's innovation capabilities in the animal health sector.
  • Strong Financial Performance: Elanco reported a non-GAAP EPS of $0.40, beating expectations by $0.06, with revenue of $1.37 billion exceeding forecasts by $90 million, demonstrating the company's robust performance amid ongoing innovation and growing market demand.
PRnewswire
7.5
06-18PRnewswire
Elanco Launches Corporate Venture Capital Platform
  • Investment Initiative Launched: Elanco Animal Health has announced the establishment of Elanco Ventures, committing $25 million to support innovation in the animal health sector, aiming to advance therapeutic technologies and supportive innovations through startup investments.
  • Strategic Focus: The platform will prioritize early-stage companies, including Pre-Seed, Seed, and Series A stages, leveraging partnerships within the One Health Innovation District in Indianapolis to enhance visibility into emerging technologies.
  • Increased Industry Relevance: CEO Jeff Simmons emphasized that the relevance of the animal health industry has never been greater, with Elanco Ventures positioned to meet evolving pet owner care expectations while addressing the rising global demand for protein.
  • Innovation Ecosystem Development: The One Health Innovation District serves as a unique ecosystem designed to converge animal, human, and plant health, accelerating the discovery-to-delivery process, with Elanco Ventures driving future advancements in animal health within this framework.
Newsfilter
7.5
06-18Newsfilter
Elanco Launches Corporate Venture Capital Platform
  • Investment Commitment: Elanco Animal Health has announced the establishment of Elanco Ventures, committing $25 million to support innovation in the animal health sector, aiming to enhance its competitive edge by investing in startups focused on therapeutic advancements and technologies.
  • Strategic Focus: The platform will prioritize early-stage companies, including Pre-Seed, Seed, and Series A funding, with a launch expected in late 2026, highlighting Elanco's commitment to capturing emerging technologies and market opportunities.
  • One Health Ecosystem: Elanco Ventures will leverage the One Health Innovation District in Indianapolis, collaborating with partners like Purdue University to drive convergence in animal, human, and plant health, aiming to accelerate innovation and meet the growing global demand for protein.
  • Leadership Team: Elanco Ventures will be overseen by experienced CVC leader Eric Steager, emphasizing the company's commitment to innovation in animal health and reshaping the future landscape through collaboration with promising startups.
PRnewswire
5.0
06-15PRnewswire
Elanco Launches First Combination Vaccine for Dogs
  • Vaccine Innovation: Elanco's USDA-approved TruCan Ultra Lyme-L4 is the first 1/2 mL combination vaccine designed to protect dogs against Lyme disease and leptospirosis, marking a significant advancement in vaccine innovation for the company.
  • Efficacy Rates: The vaccine demonstrates a 92.2% efficacy against natural infections in highly endemic areas and achieves 100% efficacy in laboratory studies, significantly enhancing canine health protection and addressing the urgent market demand for effective vaccines.
  • Reduced Injection Frequency: By reducing the vaccine dosage from 1 mL to 1/2 mL, TruCan Ultra Lyme-L4 allows veterinarians to provide comprehensive protection in a single injection, thereby improving the overall wellness visit experience for pets and reducing stress for both veterinarians and pet owners.
  • Market Timing: With the increasing risks of Lyme disease and leptospirosis, the launch of this vaccine comes at a critical time, expected to fill the vaccination gap for over 40% of at-risk dogs, further solidifying Elanco's leadership position in the animal health market.
Newsfilter
8.0
06-11Newsfilter
U.S. Accelerates Response to New World Screwworm Outbreak
  • Outbreak Threat: The potential widespread outbreak of the New World screwworm could pose a multi-billion-dollar threat to the U.S. beef industry, which is already facing economic anxiety due to near-record high beef prices exacerbated by ongoing drought conditions.
  • Funding Support: The USDA plans to distribute $100 million earlier than expected for new technologies to combat the screwworm threat, demonstrating the government's commitment to agricultural security amid rising concerns.
  • Staff Shortages: The USDA is operating with 25% fewer animal health experts than at the start of Trump's second term, which could hinder rapid response efforts, although the agency claims this has not affected its response measures.
  • Accelerated Treatments: The FDA has issued 12 emergency use authorizations since last September, allowing for the expedited use of screwworm treatments, reflecting the urgency and coordination of government efforts to address the outbreak.
CNBC
8.5
06-05CNBC
Lululemon Shares Drop 10% Amid Outlook Downgrade
  • Lululemon Stock Decline: Shares of Lululemon fell 10% before the market opened due to lackluster product launches and negative media coverage, which directly impacted investor confidence and led the company to lower its full-year outlook.
  • Job Market Data: Economists expect May's nonfarm payrolls to increase by 80,000, a slowdown from the average of 150,000 seen in the previous two months; however, stronger-than-expected private payrolls and job openings could influence market sentiment positively.
  • Quantum Computing IPO: Quantinuum's debut on Nasdaq concluded with a market value of $15.7 billion, and while the market reaction was muted, the CEO emphasized the growing need for quantum computing resources, indicating potential future demand in various sectors.
  • Biotech Stocks Surge: Following the detection of the New World screwworm in Texas, biotech companies Zoetis and Elanco Animal Health saw their stocks rise in yesterday's session, reflecting increased market interest and demand for animal health products.
Wall Street analysts forecast ELAN stock price to rise
11 Analyst Rating
Wall Street analysts forecast ELAN stock price to rise
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
22.00
Averages
25.50
High
30.00
Current: 0.000
sliders
Low
22.00
Averages
25.50
High
30.00
TD Cowen
Steve Scala
Buy
maintain
$31 -> $32
AI Analysis
2026-06-18
New
Reason
TD Cowen
Steve Scala
Price Target
$31 -> $32
AI Analysis
2026-06-18
New
maintain
Buy
Reason
TD Cowen analyst Steve Scala raised the firm's price target on Elanco to $32 from $31 and keeps a Buy rating on the shares. The firm said seven potential blockbuster launches are key catalysts for sales growth and margin expansion. These launches augment a diversified existing portfolio - including a #1 Pet Retail position which together are poised to drive +5% revenue and +10% EPS growth during 2025-32.
Morgan Stanley
Equal Weight
downgrade
$24 -> $23
2026-05-15
Reason
Morgan Stanley
Price Target
$24 -> $23
2026-05-15
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on Elanco to $23 from $24 and keeps an Equal Weight rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ELAN
Unlock Now

Valuation Metrics

The current forward P/E ratio for Elanco Animal Health Inc (ELAN.N) is 18.73, compared to its 5-year average forward P/E of 18.39. For a more detailed relative valuation and DCF analysis to assess Elanco Animal Health Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
18.39
Current PE
18.73
Overvalued PE
23.78
Undervalued PE
13.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
14.12
Current EV/EBITDA
11.32
Overvalued EV/EBITDA
17.32
Undervalued EV/EBITDA
10.93

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.87
Current PS
2.20
Overvalued PS
2.55
Undervalued PS
1.20

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

suitable for swing trade?
Intellectia · 31 candidates
Region: USVolume: >= 3,000,000Rsi Category: moderateBeta: HighRiskList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Month Price Change Pct: $-15.00 - $-3.00
Ticker
Name
Market Cap$
top bottom
ALLO logo
ALLO
Allogene Therapeutics Inc
550.94M
RKLB logo
RKLB
Rocket Lab Corp
34.69B
DNLI logo
DNLI
Denali Therapeutics Inc
2.88B
MU logo
MU
Micron Technology Inc
402.85B
NNDM logo
NNDM
Nano Dimension Ltd
355.47M
CIFR logo
CIFR
Cipher Digital Inc
5.57B
stock to swingtrade
Intellectia · 18 candidates
Market Cap: >= 5.00BBeta: HighRiskList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Week Predict Return: >= 3.0%Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
AAOI logo
AAOI
Applied Optoelectronics Inc
8.89B
ELAN logo
ELAN
Elanco Animal Health Inc
12.68B
GTLS logo
GTLS
Chart Industries Inc
9.92B
TTMI logo
TTMI
TTM Technologies Inc
11.22B
WCC logo
WCC
Wesco International Inc
13.47B
NTAP logo
NTAP
NetApp Inc
20.82B
best stock for swing trade today
Intellectia · 61 candidates
Region: USPrice: $10.00 - $100.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: $5.00 - $15.00One Week Rise Prob: 0 - 100One Week Predict Return: 0.0% - 100.0%Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
ZEPP logo
ZEPP
Zepp Health Corp
327.61M
XPRO logo
XPRO
Expro Group Holdings NV
2.07B
FCX logo
FCX
Freeport-McMoRan Inc
94.21B
AGI logo
AGI
Alamos Gold Inc
20.87B
GFI logo
GFI
Gold Fields Ltd
51.00B
VOR logo
VOR
Vor Biopharma Inc
640.24M
what stocks look ready for a breakout
Intellectia · 103 candidates
Market Cap: >= 2.00BRegion: USPrice: $10.00 - $120.00Relative Vol: >= 1.50New High Low: 52w_HighBeta: ModerateRisk, HighRisk, LowRisk, NegativeBetaList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Support Resistance Relationship: PriceBreakResistanceMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
CSCO logo
CSCO
Cisco Systems Inc
326.12B
KO logo
KO
Coca-Cola Co
335.18B
CCL logo
CCL
Carnival Corp
45.23B
RF logo
RF
Regions Financial Corp
26.27B
KEY logo
KEY
KeyCorp
24.94B
CSX logo
CSX
CSX Corp
74.09B
what stock should I trade today
Intellectia · 19 candidates
Market Cap: >= 1000.00MPrice: $5.00 - $100.00Price Change Pct: >= $3.00Beta: HighRiskList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
PSNY logo
PSNY
Polestar Automotive Holding UK PLC
1.21B
FORM logo
FORM
FormFactor Inc
5.43B
AXTI logo
AXTI
AXT Inc
1.11B
OCUL logo
OCUL
Ocular Therapeutix Inc
1.80B
BLBD logo
BLBD
Blue Bird Corp
1.58B
KLIC logo
KLIC
Kulicke and Soffa Industries Inc
2.89B
Best stock for this week
Intellectia · 92 candidates
Market Cap: >= 5.00BPrice: >= $-100.00Quarter Revenue Yoy Growth: >= 0.0%Analyst Consensus: Strong Buy, Moderate Buy, HoldList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePrice, AbovePriceMoving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $2.00Ema 20: >= -100One Week Rise Prob: >= 55Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
PR logo
PR
Permian Resources Corp
13.28B
BKH logo
BKH
Black Hills Corp
5.53B
WPC logo
WPC
W.p. Carey Inc
14.98B
ELAN logo
ELAN
Elanco Animal Health Inc
12.14B
LPLA logo
LPLA
LPL Financial Holdings Inc
30.15B
IBRX logo
IBRX
Immunitybio Inc
6.02B
best stock to hold for 30 days
Intellectia · 81 candidates
Market Cap: >= 10.00BAnalyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Month Rise Prob: >= 60One Month Predict Return: >= 5.0%
Ticker
Name
Market Cap$
top bottom
SMFG logo
SMFG
Sumitomo Mitsui Financial Group Inc
134.12B
ROST logo
ROST
Ross Stores Inc
60.99B
YPF logo
YPF
YPF SA
14.29B
FE logo
FE
FirstEnergy Corp
26.90B
NI logo
NI
NiSource Inc
20.72B
PBR logo
PBR
Petroleo Brasileiro SA Petrobras
92.03B
best stock to open for the next 30 days
Intellectia · 83 candidates
Market Cap: >= 10.00BAnalyst Consensus: Strong Buy, Moderate BuyMoving Average Relationship: PriceAboveMA20One Month Rise Prob: >= 60One Month Predict Return: >= 5.0%
Ticker
Name
Market Cap$
top bottom
SMFG logo
SMFG
Sumitomo Mitsui Financial Group Inc
134.12B
ROST logo
ROST
Ross Stores Inc
60.99B
YPF logo
YPF
YPF SA
14.29B
FE logo
FE
FirstEnergy Corp
26.90B
NI logo
NI
NiSource Inc
20.72B
PBR logo
PBR
Petroleo Brasileiro SA Petrobras
92.03B
bullish stocks under 60
Intellectia · 28 candidates
Market Cap: >= 5.00BPrice: <= $60.00Beta: HighRiskWeekly Average Turnover: >= 3,000,000Rsi 14: >= 50Moving Average Relationship: PriceAboveMA20Quarter Price Change Pct: >= $5.00Annual Eps Yoy Growth: >= 15.0%
Ticker
Name
Market Cap$
top bottom
NU logo
NU
Nu Holdings Ltd
83.54B
B logo
B
Barrick Mining Corp
82.80B
RKT logo
RKT
Rocket Companies Inc
59.75B
PAAS logo
PAAS
Pan American Silver Corp
24.15B
MRNA logo
MRNA
Moderna Inc
19.46B
HL logo
HL
Hecla Mining Co
19.35B
find similar stocks of hims and hers
Intellectia · 208 candidates
Market Cap: 300.00M - 15.00BPs Ratio: <= 15.00Is Optionable: TrueAnnual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
GH logo
GH
Guardant Health Inc
14.98B
ICLR logo
ICLR
ICON PLC
14.12B
PEN logo
PEN
Penumbra Inc
14.03B
SOLV logo
SOLV
Solventum Corp
13.94B
SNN logo
SNN
Smith & Nephew PLC
13.91B
NBIX logo
NBIX
Neurocrine Biosciences Inc
13.50B

Whales Holding ELAN

P
PRIMECAP Management Company
Holding
ELAN
+37.24%
3M Return
F
Frontier Capital Management
Holding
ELAN
+33.17%
3M Return
S
Shapiro Capital Management LLC
Holding
ELAN
+22.47%
3M Return
B
Blackhill Capital, Inc
Holding
ELAN
+20.04%
3M Return
D
Douglas Lane & Associates, LLC
Holding
ELAN
+16.67%
3M Return
B
Bowen, Hanes & Company, Inc.
Holding
ELAN
+14.97%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Elanco Animal Health Inc (ELAN) stock price today?

The current price of ELAN is 24.22 USD — it has increased 3.55

What is Elanco Animal Health Inc (ELAN)'s business?

Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.

What is the price predicton of ELAN Stock?

Wall Street analysts forecast ELAN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAN is25.50 USD with a low forecast of 22.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Elanco Animal Health Inc (ELAN)'s revenue for the last quarter?

Elanco Animal Health Inc revenue for the last quarter amounts to 1.37B USD, increased 14.92

What is Elanco Animal Health Inc (ELAN)'s earnings per share (EPS) for the last quarter?

Elanco Animal Health Inc. EPS for the last quarter amounts to 0.11 USD, decreased -15.38

How many employees does Elanco Animal Health Inc (ELAN). have?

Elanco Animal Health Inc (ELAN) has 9400 emplpoyees as of June 20 2026.

What is Elanco Animal Health Inc (ELAN) market cap?

Today ELAN has the market capitalization of 12.10B USD.